A Phase 3 interventional study of Placebo and Obicetrapib in Dyslipidemias, High Cholesterol and Hypercholesterolemia, sponsored by NewAmsterdam Pharma. Completed at 181 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by NewAmsterdam Pharma · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing TA-8995 in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. TA-8995 · Dyslipidemias.
Among the 14 studies testing TA-8995 in Dyslipidemias, this one has the largest enrollment, is one of 3 that started in 2021, is one of 3 in phase 3, and was the 9th registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →1 of the 14 studies testing TA-8995 in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:
NewAmsterdam Pharma · Sites in United States
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2021.
This study's enrollment of 2,530 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 116 across the 14 interventional studies. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 3 most frequent:
NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
NewAmsterdam Pharma has 8 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
1 of the studies testing TA-8995 in Dyslipidemias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06496243NewAmsterdam PharmaImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing TA-8995 in Dyslipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying HeFH and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy. The screening period for this study will take up to 28 days. Afterwards patients will be randomized to placebo or 10 mg obicetrapib for a 365 day treatment period. After the treatment period, patients will have an end of study follow-up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
one placebo tablet once daily
Drug: Placebo
one 10mg obicetrapib tablet once daily
Drug: Obicetrapib
placebo tablet made to resemble active
10mg obicetrapib tablet
Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]
LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).
Time frame: 84 Days
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins]
LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[Martin/Hopkins\]. LDL-C value was calculated using the Martin/Hopkins equation unless TG \>= 400 mg/dL or LDL-C \<= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC).
Time frame: 180 Days
Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC]
LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).
Time frame: 365 Days
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 84
LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.
Time frame: 84 Days
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 180
LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.
Time frame: 180 Days
Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365
LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.
Time frame: 365 Days
Percent Change in Non-HDL-C From Baseline to Day 84
LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group.
Time frame: 84 Days
Percent Change in Non-HDL-C From Baseline to Day 180
LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.
Time frame: 180 Days
Percent Change in Non-HDL-C From Baseline to Day 365
LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.
Time frame: 365 Days
Percent Change in HDL-C From Baseline to Day 84
LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.
Time frame: 84 Days
Percent Change in HDL-C From Baseline to Day 180
LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.
Time frame: 180 Days
Percent Change in HDL-C From Baseline to Day 365
LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.
Time frame: 365 Days
Percent Change in Lp(a) From Baseline to Day 84
LS mean percent change from baseline to Day 84 in Lipoprotein (a) \[Lp(a)\] in obicetrapib group compared to the placebo group.
Time frame: 84 Days
Percent Change in Apolipoprotein A1 (ApoA1) From Baseline to Day 84
LS mean percent change from baseline to Day 84 in Apolipoprotein A1 (ApoA1) in obicetrapib group compared to the placebo group.
Time frame: 84 Days
Percent Change in Total Cholesterol From Baseline to Day 84
LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group.
Time frame: 84 Days
Percent Change in Total Cholesterol From Baseline to Day 180
LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group.
Time frame: 180 Days
Percent Change in Total Cholesterol From Baseline to Day 365
LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group.
Time frame: 365 Days
Percent Change in Triglycerides From Baseline to Day 84
LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group.
Time frame: 84 Days
Percent Change in Triglycerides From Baseline to Day 180
LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group.
Time frame: 180 Days
Percent Change in Triglycerides From Baseline to Day 365
LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group.
Time frame: 365 days
4214 patients were screened: out of 4214, 2530 participants were randomized (2:1) (obicetrapib: placebo): 1686 participants to the obicetrapib 10 mg group and 844 participants to the placebo group
| Milestone | Placebo | Obicetrapib 10mg |
|---|---|---|
| Started | 844 | 1686 |
| Completed | 795 | 1600 |
| Not completed | 49 | 86 |
| Withdrew: Lost to follow-up | 16 | 38 |
| Withdrew: Withdrawal by subject | 20 | 27 |
| Withdrew: Death | 11 | 17 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Participant moved away | 0 | 2 |
| Withdrew: Adverse event | 2 | 1 |
LS mean percent change from baseline to Day 84 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] | 2.70 ± 1.571 | -29.94 ± 1.104 |
LS mean percent change from baseline to Day 180 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[Martin/Hopkins\]. LDL-C value was calculated using the Martin/Hopkins equation unless TG \>= 400 mg/dL or LDL-C \<= 50 mg/dL; where, LDL-C value was measured directly by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 180 [Martin/Hopkins] | 4.68 ± 1.625 | -29.09 ± 1.176 |
LS mean percent change from baseline to Day 365 in Low-Density Lipoprotein Cholesterol (LDL-C) in the obicetrapib group compared to the placebo group \[PUC\]. LDL-C level was measured by preparative ultracentrifugation (PUC).
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline to Day 365 [PUC] | -1.27 ± 1.798 | -25.25 ± 1.480 |
LS mean percent change from baseline to Day 84 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 84 | 1.08 ± 0.911 | -17.84 ± 0.669 |
LS mean percent change from baseline to Day 180 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 180 | 2.23 ± 1.033 | -16.07 ± 0.742 |
LS mean percent change from baseline to Day 365 in apolipoprotein B (ApoB) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Apolipoprotein B (ApoB) From Baseline to Day 365 | -1.77 ± 1.165 | -15.57 ± 0.914 |
LS mean percent change from baseline to Day 84 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Non-HDL-C From Baseline to Day 84 | 2.81 ± 1.212 | -26.64 ± 0.892 |
LS mean percent change from baseline to Day 180 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Non-HDL-C From Baseline to Day 180 | 3.68 ± 1.302 | -24.63 ± 0.972 |
LS mean percent change from baseline to Day 365 in Non-high-density Lipoprotein Cholesterol (non-HDL-C) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Non-HDL-C From Baseline to Day 365 | 0.63 ± 1.480 | -22.38 ± 1.186 |
LS mean percent change from baseline to Day 84 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in HDL-C From Baseline to Day 84 | 0.61 ± 1.391 | 136.87 ± 1.857 |
LS mean percent change from baseline to Day 180 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in HDL-C From Baseline to Day 180 | 1.18 ± 1.897 | 135.61 ± 2.192 |
LS mean percent change from baseline to Day 365 in High-density Lipoprotein Cholesterol (HDL-C) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in HDL-C From Baseline to Day 365 | 3.36 ± 1.651 | 125.40 ± 2.193 |
LS mean percent change from baseline to Day 84 in Lipoprotein (a) \[Lp(a)\] in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Lp(a) From Baseline to Day 84 | 13.65 ± 8.240 | -0.48 ± 19.855 |
LS mean percent change from baseline to Day 84 in Apolipoprotein A1 (ApoA1) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Apolipoprotein A1 (ApoA1) From Baseline to Day 84 | 0.26 ± 0.597 | 43.44 ± 0.686 |
LS mean percent change from baseline to Day 84 in Total Cholesterol (TC) in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Total Cholesterol From Baseline to Day 84 | -0.02 ± 0.757 | 17.66 ± 0.702 |
LS mean percent change from baseline to Day 180 in Total Cholesterol in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Total Cholesterol From Baseline to Day 180 | 0.85 ± 0.893 | 18.68 ± 0.769 |
LS mean percent change from baseline to Day 365 in Total Cholesterol in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Total Cholesterol From Baseline to Day 365 | -0.58 ± 1.030 | 17.96 ± 0.886 |
LS mean percent change from baseline to Day 84 in Triglycerides in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Triglycerides From Baseline to Day 84 | 7.66 ± 1.814 | -0.17 ± 1.445 |
LS mean percent change from baseline to Day 180 in Triglycerides in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Triglycerides From Baseline to Day 180 | 8.22 ± 2.061 | 0.25 ± 1.584 |
LS mean percent change from baseline to Day 365 in Triglycerides in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Triglycerides From Baseline to Day 365 | 6.33 ± 2.135 | 0.60 ± 1.781 |
Median percent change from baseline to Day 84 in Lipoprotein (a) \[Lp(a)\] in obicetrapib group compared to the placebo group.
| percent change from baseline | Placebo | Obicetrapib 10mg |
|---|---|---|
| Percent Change in Lp(a) From Baseline to Day 84 (Hodges-Lehman) | -0.9 (-15.7 to 13.0) | -32.3 (-62.8 to -4.7) |
Collected over From first dose of study drug up to Week 54. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 12/843 (1.4%) | 117/843 (13.9%) | 241/843 (28.6%) |
| Obicetrapib 10mg | 19/1,685 (1.1%) | 211/1,685 (12.5%) | 459/1,685 (27.2%) |
| Event | Placebo | Obicetrapib 10mg |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 10/843 | 17/1685 |
| Angina unstableCardiac disorders | 8/843 | 17/1685 |
| Myocardial infarctionCardiac disorders | 7/843 | 3/1685 |
| PneumoniaInfections and infestations | 6/843 | 9/1685 |
| Coronary artery diseaseCardiac disorders | 4/843 | 7/1685 |
| Cardiac failureCardiac disorders | 4/843 | 5/1685 |
| Acute left ventricular failureCardiac disorders | 4/843 | 2/1685 |
| Angina pectorisCardiac disorders | 0/843 | 7/1685 |
| Cerebral infarctionNervous system disorders | 2/843 | 7/1685 |
| Cerebrovascular accidentNervous system disorders | 1/843 | 7/1685 |
| Event | Placebo | Obicetrapib 10mg |
|---|---|---|
| COVID-19Infections and infestations | 48/843 | 81/1685 |
| HypertensionVascular disorders | 33/843 | 82/1685 |
| Upper respiratory tract infectionInfections and infestations | 33/843 | 49/1685 |
| HyperglycaemiaMetabolism and nutrition disorders | 28/843 | 44/1685 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/843 | 38/1685 |
| NasopharyngitisInfections and infestations | 22/843 | 43/1685 |
| HeadacheNervous system disorders | 17/843 | 43/1685 |
| Urinary tract infectionInfections and infestations | 21/843 | 39/1685 |
| DizzinessNervous system disorders | 15/843 | 40/1685 |
Baseline Population is defined as all randomized participants.
| Age, Continuous(years) | Placebo | Obicetrapib 10mg | Total |
|---|---|---|---|
| Mean | 65.3 ± 9.61 | 65.4 ± 9.90 | 65.4 ± 9.80 |
| Sex: Female, Male(Participants) | Placebo | Obicetrapib 10mg | Total |
|---|---|---|---|
| Female | 280 | 573 | 853 |
| Male | 564 | 1113 | 1677 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Obicetrapib 10mg | Total |
|---|---|---|---|
| Hispanic or Latino | 46 | 80 | 126 |
| Not Hispanic or Latino | 798 | 1605 | 2403 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Obicetrapib 10mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 5 | 6 |
| Asian | 150 | 312 | 462 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 39 | 112 | 151 |
| White | 647 | 1241 | 1888 |
| More than one race | 2 | 7 | 9 |
| Unknown or Not Reported | 5 | 9 | 14 |
| Baseline Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL) | Placebo | Obicetrapib 10mg | Total |
|---|---|---|---|
| Mean | 98.4 ± 37.94 | 98.1 ± 37.05 | 98.25 ± 37.5 |
Showing the first 100 of 181 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Sep 2024, 33 months.
Results were first posted in Sep 2025, 11 months after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 33 months is above that.
Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TA-8995
NewAmsterdam Pharma